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Medulloblastoma (MB) is a primitive neuroectodermal 
tumor that arises from granule neuron precursors in the 
cerebellum or from neural stem cells of the rhombic lip 
and is the most frequently diagnosed malignant brain 
tumor in children [1]. Approximately 70% of MB cases 
occur in children under the age of 10.  While less 
common, MB is also seen in patients between 20 and 44 
years of age, with incidences falling off significantly 













































chemotherapy has contributed to improved treatment 
outcomes, resulting in a 70-80% five-year disease-free 
patients with medulloblastoma remain significant and 
recurrence is frequently observed. As with many malig-
nancies, disease recurrence is nearly always fatal, and late 
mortality remains a serious health issue in long-term MB 
survivors [2].  Moreover, current therapies result in 
significant negative impacts on neurological, cognitive and 
social development, especially in the youngest affected 
children. Significant efforts are therefore underway to 
develop more effective and less toxic MB treatments. 
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The efficacy of many anti-tumor agents relies on their 
ability to trigger the tumor suppressive activities of p53, 
which leads to the induction of cell death, frequently via 
cellular pathways of apoptosis, senescence or mitotic 
catastrophe. While the activity of the p53 tumor 
suppressor protein is highly complex [3], its expression 
is induced by a broad array of cell stressors including 
DNA-damaging chemotherapeutic drugs and can be an 
excellent target for therapeutic intervention ([4], see 
also [3]). Impairment of p53 signaling by gene mutation 
or gene silencing/loss has been shown to contribute to 
the induction, progression and/or recurrence of many 
tumor types and can confer resistance to tumor therapy.  
p53 plays unique roles in neural development. For 
example, p53 has been directly implicated in 
neurogenesis as well as in neural stem cell self-renewal, 
neurite outgrowth and axonal regeneration (reviewed in 
[5]), and acetylation of p53 is required for the induction 
of neurite outgrowth [6]. Despite this knowledge and 
that related to the role of p53 in many malignancies, the 
function of p53 in MB remains under-explored. For 
example, unlike lung, pancreas and bladder cancers, 
only a minority of primary MB patients present with 
p53 mutation or loss, with reported frequencies between 
7% [7] and 15% [8]. Interestingly, while the frequency 
of p53 mutations increases upon recurrence, the 
percentage of cells with nuclear p53 also increases, 
rising from 26% at diagnosis to 33% at relapse [8], 
suggesting that certain mechanisms underlying p53 
function may still be intact. Importantly, the MAGIC 
consortium identified chromosome 17 deletions, where 
the p53 locus is located, to be associated with 
chromothripsis (chromosomal fragmentation) in Group 
3 MB [9], while reduced expression of p53 was seen in 
Group 4 MB [10]. Collectively, these findings 
highlight the complex and poorly defined role for p53 
in human MB, and support the need for mechanistic 
studies into p53 activity as a possible therapeutic 
effector protein. 
 
The in vitro [11-13] and in vivo [14] anti-tumor 
activities of an experimental CDK inhibitor, VMY-1-
103 (VMY), have previously been described by us in 
both prostate and other solid tumors [11, 13, 15] and in 
MB [12, 14]. Our previous MB studies established that 
the extrinsic apoptotic pathway was induced by VMY, 
as was mitotic catastrophe in a subset of the cells [12]. 
In the present study, we sought to further define the 
molecular and genetic mechanisms by which VMY 
induces MB cell death.  Herein, we show in both p53-
wild type (D556) and p53-mutant (DAOY) MB cells 
lines that treatment with VMY resulted in the 
translocation of p53 into the nucleus, an induction of 
γH2AX, a decrease in MDM2 protein levels and 
activation of non-survival macro-autophagy. 
Interestingly, suppression of p53 function via shRNA 
knockdown or treatment with the p53 inhibitory 
compound Pifithrin-α (Pif) [16] resulted in significant 
increases in cell death following treatment with either 
VMY or doxorubicin. Gene expression analyses 
performed on D556 cells treated with VMY and Pif 
versus VMY alone revealed a significant increase in 
genes associated with apoptosis and necrosis, including 
the calcium pathway signaling genes CAPN12 and 
TRPM8 suggesting alterations in intracellular calcium 
signaling may play a role in enhancing cell death. In 
addition, p63 and its transcriptional target the pro-
apoptotic gene BIK were induced, as were p73 and its 
target, the caspase-independent intranucleosomal 
DNase, Endonuclease-G (Endo-G) [17].  
 
Given the difficulties in effectively treating MB, 
especially recurrent disease, targeting p53 in 
combination with chemotherapy potentially represents a 




Treatment of MB cells induces a durable cytotoxic 
effect 
 
We have previously reported that VMY induces MB cell 
death [12, 14]. To test whether VMY’s antiproliferative 
effects were sustained after removal of the compound, 
colony forming assays were performed. D556 cells were 
treated with VMY or its parent compound purvalanol B 
(PVB) for 18 hrs, at which point the media was changed 
and the cells were allowed to recover in the absence of 
the drugs until the control plate reached 80% confluency 
(approximately 3-5 days). VMY treatment resulted in a 
significant reduction in both the number of colonies (Fig 
1A, B, C) as well as the number of cells per colony (Fig 
1D) versus either DMSO- or PVB- treated D556 cells, 
which express wild type p53. The DNA damaging drug, 
doxorubicin (1uM), effectively killed all cells (not 
shown).  
 
VMY induces a partial DNA damage-like response 
in DAOY and D556 MB cell lines 
 
Our previous studies established that the induction of 
cell death in MB cells occurred, at least in part, through 
the extrinsic apoptotic pathway and mitotic disruption 
[12, 14]. To further investigate the mechanisms by 
which VMY impacts cell survival, we interrogated 
proteins involved in DNA damage response and stress 
signaling. Time course studies of VMY treatment were 
performed first in DAOY cells, which express mutant 
p53 (p53C252F). Doxorubicin was used as a positive 
control for induction of a DNA damage response [18],  
  



















































































































DMSO, PVB, VMY or doxorubicin at  the concentrations  listed and  immunoblotting was performed
for the proteins shown. β‐actin was used as a loading control. PVB; purvalanol B, Doxo; doxorubicin. 
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and PVB was also tested. Compared to DMSO control, 
treatment with doxorubicin for 18 hours increased the 
levels of phosphorylated isoforms of ATM, Chk2, 
γH2AX, BRCA1 and p38 (Fig. 2) as well as ATR, 
pS46-p53 and Chk1 (Fig 2). A modest increase in 
mTOR was also noted. In contrast, the levels of all of 
these proteins, with the exception of p-γH2AX (Fig 2) 
and to a lesser extent mTOR, were reduced following 














































manner similar to doxorubicin despite the fact that PVB 
is an inefficient inhibitor of MB cell proliferation [12]. 
In contrast to DAOY cells, the levels of total- and 
phospho- p38 remained relatively constant in D556 
cells and phospho-p38 decreased slightly following 18 
hrs of VMY treatment (Fig 3A), however sustained 
induction of γH2AX was confirmed by western blot and 
by immunofluorescence in both DAOY and D556 cells 




















































viability.  (A)  D556  cells,  transfected  with  LC3‐GFP,
were  treated  with  DMSO  or  VMY  for  4  and  18  hrs.
Autophagic  LC3‐GFP  puncta  were  visualized  by
fluorescence microscopy. Cell nuclei were stained with
DAPI.  (B) D556 and  (C) DAOY  cells were  treated with
VMY for 18hrs  in the presence or absence of 5 uM 3‐
MA  (an  inhibitor  of  early  autophagy)  or  50  uM
chloroquine  (an  inhibitor of acidification of  lysosomes
and autophagosomes), and trypan blue viability assays
were performed to establish cell viability. The data are
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VMY induces autophagy in MB cells 
 
VMY has the ability to block proliferation in prostate 
cancer cells in part through the induction of catastrophic 
autophagy [15]. During autophagy, LC3-I (microtubule-
associated protein 1 light chain 3) becomes lipidated by 
the class III phosphoinositide 3-kinase, Vps34, and re-
localizes from the microtubules to autophagosomal 
membranes (reviewed in Kang, et al. [19]). We 
therefore studied the pattern of subcellular localization 
of LC3-I in MB cells. D556 cells were transiently 
transfected with an LC3-GFP expression vector and 
subjected to fluorescence microscopy as previously 
described [15]. VMY treatment induced LC3-GFP re-
localization and concentration into prototypical 
autophagic puncta (Fig 4A) with an average of 6 puncta 
per VMY-treated, LC3-GFP positive cell at 4 hours and 
7.8 puncta per cell at 18 hrs, versus an average of 2.3 
puncta per cell in control cells (Fig 4A). Our previous 
data established that inhibition of autophagy protected 
against VMY-induced cell death in prostate cancer cells 
[15]. We therefore investigated whether inhibitors of 
early (3-methyladenine, 3-MA) or late (chloroquine, 
CQ) autophagy  influenced  cell  survival.  Using  D556  
and DAOY cells, trypan blue dye exclusion assays 
established that neither 3-MA nor CQ influenced 
survival in control cells, however significant increases 
(p<0.05, N=3 separate experiments) in cell viability 
were seen in both cell lines when treated with VMY and 

























Regulation of p53 activity is similar in DAOY and 
D556 MB cell lines 
 
Our earlier investigations into the mechanisms by which 
VMY reduced overall cell survival in solid tumors 
clearly established a role for wild type p53 in inducing 
cell death through both apoptosis and catastrophic 
autophagy. For example, in adenocarcinoma cell lines 
with wild type p53, VMY caused a rapid induction of 
p53 protein levels whereas p53 levels remained constant 
in cells harboring p53 mutations [15]. Furthermore, the 
loss of p53 function via deletion, mutation or genetic 
silencing resulted in a complete loss of VMY-induced 
cytotoxicity in a variety of cancers, including prostate, 
breast and pancreas, while re-expression of wild type 
p53 in PC3 cells or treatment of DU145 cells with 
PRIMA1 restored VMY-induced autophagy and cell 
death [11, 15].  
 
We therefore next investigated the effects of VMY on 
p53 expression in DAOY (p53 C242F mutant [20]) and 
D556 cells (p53 wild type). Unlike our previous 
findings in adenocarcinoma cells, p53 levels were high 
in both cell lines and were not affected by treatment 
with VMY (Supplemental Fig. 1). Similar results were 
seen with PVB (Supplemental Fig. 1). The levels of the 
p53-regulatory protein MDM2 were decreased in both 
cell lines (Fig 5A) and immunofluorescence microscopy 
demonstrated that p53 shifted from diffusely cyto-
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predominantly nuclear in both cell lines following 
VMY treatment (Fig 5B). As both the wild type and 
mutant p53 proteins localize to the nucleus following 
exposure to VMY, these data suggest that both proteins 
may retain some functional activity. 
 
The role of p53 in inducing cell death 
 
To determine the role of p53 in regulating MB cell 
survival in the presence of VMY, p53 was genetically 
silenced with the previously validated p53 shRNA [15] or 
chemically inhibited by the p53-inhibitory compound, 
Pifithrin-α (Pif), which we have used in previous 
experiments to investigate p53’s role in regulating 








































in up to a 68% decrease in p53 protein levels versus 
pLKO control across all treatment groups in both D556 
and DAOY cells (Fig 6A). Surprisingly, both the genetic 
and chemical silencing of p53 led to significant increases 
in cell death by VMY as measured by colony forming 
assay (Fig 6B). Equally surprising was the observation 
that the loss of p53 failed to protect against cell death by 
doxorubicin (Fig 6B, C). Dose escalation experiments 
performed in D556 cells in the presence and absence of 
Pif established that the heightened chemosensitivity was 
consistent across a broad range of concentrations (Fig 
6D). In addition, experiments performed in DAOY 
showed that cell-survival declined by 33 percent in 
VMY-treated cells with p53 shRNA knockdown com-










































Figure 6. Effects of  silencing of p53 on  cell  survival.  (A) Genetic  silencing of p53. D556 and DAOY  cells were  infected with 
p53siRNA or pLKO  lentivirus’. The cells were  left untreated or exposed for 18 hrs to DMSO or 30uM VMY as  indicated, and western 













































Loss of p53 in the presence of VMY alters calcium, 
p63 and p73 signaling pathways 
 
In order to more completely define the mechanism 
underlying the paradoxical effect of p53 silencing, 
RNAseq next generation sequencing was performed on 
D556 cells treated with VMY in the presence or 
absence of Pif. RNA sequence analysis revealed an 
increase in expression of calpain 12 in the VMY/Pif 
treated cells vs. VMY/DMSO control cells (Table 1). In 
addition, elevated expression of the transient receptor 
potential channel subfamily (TRPM8) gene was seen 
(Table 1), collectively suggesting that intracellular 
calcium signaling pathways were affected by p53 
silencing. Dysregulation of the calcium signaling 
pathway downstream of stressors such as excitotoxicity 







































[21, 22]), with one of the hallmarks of necrosis being 
Endo G induction and intranucleosomal DNA cleavage 
[22]. As both the pro-apoptosis regulatory genes p63 and 
p73 were induced by p53 silencing, as were possible 
downstream targets including Endo-G [23], the pro-
apoptotic BH3-protein, BIK (Bcl-2-interacting killer) and 
CIDEB (cell death-inducing DFFA-like effector B), we 
assessed levels of late stage apoptosis and necrosis by 
flow cytometry, by gating for annexin V-
positive/propidium iodide (PI)-positive cells. D556 cells 
were infected with either pLKO or p53shRNA as 
described above and treated for 18-hours with DMSO, 
30uM VMY or 1uM doxorubicin, after which they were 
analyzed by flow cytometry as previously described [15]. 
While the annexin-/PI+ fraction of cells was unaffected, 
the silencing of p53 increased the proportion of annexin 
V+/PI+ cells following exposure to VMY  or  doxorubicin  
Table 1. Top 25 genes altered in the presence of Pifithrin α plus VMY 
vs. VMY alone. 
Pif + VMY vs. VMY 
Up-regulated Fold Down-regulated  Fold 
EndoG 8.77809E+30 FIGF -6.10476E+11 
CIDEB 1.9687E+12 ANGPT4 -6.017072518 
PRSS54 1299.03 GSK3A -5.35 
BIK 19.44 INCA1 -5.18 
MAP3K9 18.19 TNFSF14 -4.01 
ERBB3 15.17 GDF15 -4.01 
BRAT1 7.48 HGF -3.89 
CISH 6.73 BIRC3 -3.41 
FADD 6.73 LIF -2.85 
TP63 6.63 NTF3 -2.77 
CBX6 6.23 DRD2 -2.75 
SRC 5.98 SNCG -2.67 
CBX7 5.98 MAGEA9 -2.67 
HDAC4 5.24 ZNF385D -2.67 
RASSF4 4.49 CRIP3 -2.67 
TRPM8 4.49 TNFSF15 -2.45 
ERBB2 4.06 NAP1L6 -2.45 
AKT1 3.84 TENC1 -2.33 
UNC5B 3.83 NRCAM -2.23 
TNFRSF10D 3.74 DNAJB7 -2.21 
NLRP12-14 3.74 MAGEB2 -2.19 
TP73 3.74 PPAPDC2 -2.14 
ARHGEF18 3.55 PRSS12 -2.14 
TNFRSF25 3.49 CFLAR -2.07 
FASTK 3.48 GADD45A -2.07 
  
























(Fig 7A). Finally, similar effects were seen using 
agarose gel electrophoresis assays where 18-hour 
treatment with VMY or doxorubicin plus p53shRNA 
resulted in enhanced DNA degradation, indicative of 
necrosis and apoptosis (Fig 7B). 
 
Taken together, these experiments show that p53 
protects against drug-induced cell death in 
medulloblastoma cells and its genetic- or chemical- 
suppression results in a significant increase in cell 
sensitivity to VMY and doxorubicin, an experimental 




Necrosis, apoptosis and autophagy are activated under a 
variety of cell stress conditions (see references [24, 25] 
among others), however, little is known about how 
these complex and partially overlapping mechanisms 
are induced in medulloblastoma cells. In addition, to 
date, there have been few publications exploring the 
effects in medulloblastoma cells of the synthetic 
modulation of p53 activity during exposure to 
chemotherapeutic drugs. 
  
We have recently shown in prostate cancer cell lines as 
well as in primary prostate cancer cells established 
using our conditional cell reprogramming approach [26, 
27], that the induction of p53 by VMY was a 
prerequisite for inducing both autophagy and apoptosis, 
and that silencing p53 effectively blocked cell death 
























on MB established that this experimental drug induced 
apoptosis and mitotic catastrophe in vitro [12]. 
Furthermore, while our in vivo studies showed that 20 
mg/kg of VMY administered three times per week for 
more than four weeks was well tolerated and was 
effective at treating a mouse model of SHH-driven 
medulloblastoma [14], a detailed investigation into the 
mechanism of VMY-induced cell death, and the role that 
p53 may play had not been explored. We now show that 
in MB cells, VMY induces the relocalization of p53 into 
the nucleus, an accumulation of γH2AX, a decrease in 
MDM2 protein levels and activation of non-survival 
macro-autophagy. Since the protein levels of key stress-
related proteins were reduced by VMY, the possibility 
existed that components of the CAP-dependent protein 
translation pathway may be inhibited by VMY. MNK1 is 
a target of p38 and MAPK and acts to increase CAP-
dependent translation through the phosphorylation of the 
elongation factor eIF4E [28]. 4E-BP1 is a negative 
regulator of translation and phosphorylation of 4E-BP1 
by mTOR inhibits its repressor function. Thus, if VMY 
negatively regulated CAP-dependent translation, the 
phosphorylation levels of 4E-BP1 and pMNK1 would be 
expected to reduce, however VMY increased the levels 
of these proteins in both D556 and DAOY cells (S.W and 
C.A, unpublished data). Interestingly, rather than 
protecting against chemotherapeutic cell killing, the 
suppression of p53 through shRNA knoc kdown or 
chemical inhibition by Pifithrin-α resulted in a significant 
increase in cell death by either VMY or doxorubicin, 
suggesting that p53 acts as a chemoprotective protein in 
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Regarding its function in the neuroectoderm, p53 
performs roles different to those found in other tissues. 
In the past decade a role for p53 has emerged in 
neuronal differentiation, axon guidance, neurite 
outgrowth and axonal regeneration [29, 30]. Analysis of 
p53-dependent transcriptional activation in normal 
development in vivo by using a lacZ reporter gene under 
the control of a p53-responsive promoter showed that 
p53 activity was maximal during neuronal 
differentiation and clustered in areas that showed little 
correlation with the apoptosis normally ongoing in the 
developing nervous system [31, 32]. Furthermore, other 











































p53-null mice developed exencephaly due to cellular 
overgrowth, rather than decreased apoptosis [33, 34]. 
 
The dependence of neurite outgrowth and elongation on 
p53 has also been shown in the developing cerebellum. 
Gaub et al., 2010 showed that acetylated p53 is required 
for neurite outgrowth in cerebellar granule cell 
progenitors. Conversely, the loss of the function acetyl 
p53 mutant (K-R) inhibits physiological neurite 
outgrowth in those cells [35]. In cultured rat cerebellar 
granule cells, Maruoka et al., 2011, showed a p53-
mediated neuroprotective effect against glutathione 















































and CIDEB expression  leading to DNA fragmentation while  increased  levels of p63  induced apoptosis though BIRC3 and BIK, the  latter of
which along with TRPM8 can influence intracellular calcium levels. BAD; BCL2‐Associated Agonist Of Cell Death, BIK; BCL2‐Interacting Killer
(Apoptosis‐Inducing), BIRC3; baculoviral IAP repeat containing 3 (cIAP2), BRAT1; BRCA1‐Associated ATM Activator 1, CAPN; Calpain, CALB1;
Calbindin  1,  CDKN2D;  Cyclin‐Dependent  Kinase  Inhibitor  2D  (p19Ink4D),  CIDEB;  Cell  Death‐Inducing  DFFA‐Like  Effector  B,  EndoG;
Endonuclease G, FADD; Fas‐Associated Via Death Domain,  INCA1;  Inhibitor Of CDK, Cyclin A1  Interacting Protein 1, NF‐KappaB; Nuclear
Factor Of Kappa Light Polypeptide Gene Enhancer In B‐Cells, TRPM8, Transient receptor potential cation channel subfamily M member 8. 
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Further validation of the role for p53 in neurite 
outgrowth and neuronal differentiation and maturation 
comes from studies establishing p53 as a downstream 
target of neurotrophic receptors. Loss of function 
experiments of p53 via either gene silencing or 
dominant negative p53 proteins lacking transactivation 
capacity have been shown to block NGF-dependent 
neurite outgrowth and differentiation in PC-12 cells [6, 
37]. Another neurotrophic factor, BDNF, has also been 
shown to stimulate p53 phosphorylation and 
transcriptional activation in primary cortical neurons 
[30]. Activation of signaling molecules downstream of 
NGF or BDNF that are known to induce p53 post-
translational modifications and enhance its 
transcriptional activity has been reported, including 
ERK1 and ERK2, p38MAPK, JNK1-2 (c-Jun N-
terminal kinases 1-2), cytoskeleton remodeling genes, 
such as GAP-43, the actin-binding protein Coronin 1b 
and the RAS family member Rab13 [6, 38]. 
 
Unresolved however is an actual role for p53 in the 
biology of human MB. Frequencies of p53 mutations are 
low in primary MB but increase significantly in 
recurrences, and mutant p53 proteins and Myc may 
collaborate to drive aggressive disease [8]. Additionally, 
modifications of p53 function are required in Myc- [39, 
40] but not Smoothened- based mouse models to drive 
MB.  The genetic silencing of p53 in mice with 
conditional deletion of the BRCA2-interacting protein 
(BCCIP) gene also resulted in MB [41]; however the 
resulting tumor formation was predicated upon the loss of 
the BCCIP knockdown cassette, which restored BCCIP 
expression in the neuroectoderm, supporting a role for 
p53 in neuronal genomic stability. Interestingly, p53 
expression levels are lower in group 4 MB, due to the 
iso-dicentric (17)(p11.2) recombination events frequently 
seen in this group [10]. However, neither the levels of 
p53 expression nor its subcellular localization were 
reported following chemotherapy. It should be noted that 
etoposide induced p53 activity in D283, MEDI and D458 
MB cell lines in vitro [42] and the p53 target miR-34a 
was able to reduce the viability in the p53-impared MB 
cell line, MEB-Med8a [43], however the effects of 
silencing of p53 per se were not reported. Furthermore, 
docosahexaenoic acid and etoposide were found to 
reduce the levels of MDM2 in both p53-mutant DAOY 
cells as well as in p53-wildtype D283 cells [44] and we 
also observe decreases in MDM2 with VMY, along with 
rapid translocation of p53 into the nucleus.  Collectively 
these published studies and our new data suggest that 
components of the p53 pathway remain intact in a variety 
of p53-mutant and p53-wild type MB cells.  
 
It was therefore surprising that rather than causing 
chemotherapeutic resistance, the suppression of p53 
function by either shRNA knockdown or Pif sensitized 
DAOY and D556 cells to both VMY and doxorubicin. 
Mechanistically, the induction of the p63 and p73 and 
their targeted genes by VMY in the Pif-treated cells was 
one of the most prominent features (Table 1 and Figure 
8). These p53 family-member genes, and their various 
splice variants, play both similar and distinct roles in 
development as well as in cancer (reviewed in [45]) and 
can interact with each other with a high degree of 
complexity. There is abundant evidence that modulation 
of p53 function can influence the activity of p63 and 
p73 (reviewed in [46]) and conversely that p63 and p73 
can influence p53 activity in adult neural precursor cells 
[47]. While the mechanism(s) by which the genetic 
knockdown or chemical suppression of p53 regulates 
p63 and p73 expression in MB cells has yet to be 
elucidated, our data suggest that the induction of p63 
and p73 following p53 suppression fundamentally alters 
the pro-apoptotic machinery in MB cells (Fig 8). It is 
also unknown whether the increased sensitivity seen in 
the cell lines tested extends to a broader array of clinical 
samples or to the chemo-radiation interventions 
currently used for treating MB. However as both 
DAOY and D556 cells show similar sensitivities to p53 
functional blockade, the possibility exists that at least a 
subset of the p53 mutations found in MB patients may 
not adversely impact p53-targeting regimens. 
Additional experiments assessing whether the p53 
mutant proteins identified in recurrent MB exhibit 
similar responses to combined p53 suppression and 
exposure to VMY, doxorubicin or other drugs are 
clearly warranted. 
 
MATERIALS AND METHODS 
 
Cell lines and cell culture. The human medulloblastoma 
(MB) cell lines D556 and DAOY were maintained in 
complete DMEM containing 10% FBS, L-glutamine, 
and 100 U/ml Penicillin-Streptomycin as previously 
described [12]. DNA STR fingerprint analyses were 
performed on both cell lines as a quality control 
measure. The DAOY data matched the ATCC database 
for this line, while early and late passage D556 cultures 
were compared with no significant changes observed 
and no matches with the available STR database (not 
shown).  
 
Cell viability and growth. Cell viability was determined 
using trypan blue dye exclusion and viable and total cell 
counting using a hemocytometer as previously 
described [11, 12, 15]. 
 
Colony forming assays. A total of 1000 cells were 
plated in 6 well plates. Cells were allowed to adhere for 
24 hrs before treatment, at which point they were 
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treated with VMY or Doxorubicin for 18 hrs. The media 
was changed after 18hrs and the plates were incubated 
in the absence of drug for 3-5 days to reach 80% 
confluency in the negative control wells. Cells were 
washed with PBS, fixed with 10% neutral buffered 
formalin solution for 15-30 minutes and stained with 
0.5% (w/v) crystal violet for 30-60 minutes. The crystal 
violet was aspirated, cells were washed with PBS and 
dried for one hour before counting. 
 
Flow cytometry. The prostate cells were fixed and 
stained with 20ug/ml propidium iodide (PI) and 5 U 
RNase A, and the DNA content and subG1 DNA 
fragmentation was measured using a FACStar Plus 
system (Becton-Dickson, Franklin Lakes, NJ) as 
previously described [11, 12]. Cellular apoptosis was 
also assessed by APC-Annexin V antibody (Biolegend, 
San Diego, CA) staining immediately after treatment 
with VMY and analyzed using FACStar Plus dual laser 
FACSort system (Becton-Dickson, Franklin Lakes, NJ) 
as previously described by us [11, 12, 48, 49].  
 
Immunoblotting.  Protein extracts were prepared and 
separated on 4-20% Tris-glycine gels and electro-
blotted onto PVDF membranes as previously described 
[11, 12, 50]. Protein levels were assessed using 
antibodies against p53 (Millipore, Bellerica, MA #05-
224), p-ATM (Cell Signaling, Danvers, MA #5883P), 
p-Chk2 (Cell Signaling, Danvers, MA #2661P), p-Chk1 
(Cell Signaling, Danvers, MA #2348P), p38 (Cell 
Signaling, Danvers, MA #8690), histone γ-H2AX (Cell 
Signaling, Danvers, MA #7631), p-histone γH2AX 
(Cell Signaling, Danvers, MA #9718P), p-BRCA1 
(Ser1524) (Cell Signaling, Danvers, MA #9009P), p-
P38 MAPK (Cell Signaling, Danvers, MA #9216S), 
mTOR (Cell Signaling, Danvers, MA #2983), p-ATR 
(Cell Signaling, Danvers, MA #2853P), p-p53 (Cell 
Signaling, Danvers, MA #9286P), p-MNK1 (cell 
signaling, #2111S), p-4E-BP1 (Cell Signaling, Danvers, 
MA #2855S), MDM2 (Santa Cruz Biotechnology, #sc-
965), β-actin (Cell Signaling, Danvers, MA #4967). 
Densitometry was performed using ImageJ analysis 
software (NIH, Bethesda, MD) as previously described 
[11, 12, 50].   
 
Immunofluorescent imaging. Cells were seeded on glass 
coverslips and treated with DMSO or VMY for 4 or 18 
hrs. Cells were washed with PBS and fixed in 10% 
formalin for 10 min. The coverslips were washed three 
times with PBS, the cells were permeabilized with 0.1% 
Triton X-100 and washed three times with PBS. The 
samples were blocked with 1% BSA for 20 minutes and 
washed an additional three times in PBS. The cells were 
exposed to anti-p53 (1:150, Millipore #05-224) or anti- 
γH2AX (1:150, Cell Signaling #7631) antibodies for 1 
hr at room temperature. The slides were washed with 
PBS an additional three times and stained with the 
secondary antibody Alexa Fluor goat 488 anti-mouse 
(1:150, Life Technologies, A-10667) for 30 min at room 
temperature. Slides were then counter-stained with 
DAPI for 5 min. The coverslips were mounted onto 
glass slides with Tris-buffered fluoro-gel (Electron 
Microscopy Sciences). Confocal microscopy was 
performed on a Zeiss (Thornwood, NY) LSM510 Meta 
microscope using a 40x lens.  
 
LC3-GFP. LC3 translocation was detected using the 
green fluorescent protein (GFP)-fused LC3 construct 
that was generously donated by Dr Robert Clarke [51]. 
Briefly, cells were seeded in 6 well plates containing 
glass coverslips and allowed to attach overnight. The 
LC3-GFP expression plasmid (14ug) was transfected 
using Lipofectamine LTX reagent (Life Technologies, 
Carlsbad, CA #15338-100) as previously described by 
us [15]. 24 hours after transfection, the cells were 
treated with VMY or vehicle. After 18 hours, the 
coverslips with attached cells were stained with DAPI 
and rinsed 3 times with PBS and the coverslips 
mounted. Imaging was performed by confocal 
microscopy as previously described [12, 15]. 
 
Autophagy inhibitors. For autophagy inhibition, 3-
methyladenine (3-MA) (Sigma-Aldrich, St Louis, MO 
#M921) was used at 5mM and chloroquine diphosphate 
(CQ) (Sigma-Aldrich, St Louis, MO #C6628) was used 
at 50 µM as previously described [15].  Cells were 
exposed to these inhibitors for 20 minutes prior to 
treatment with either DMSO or VMY [15]. 
 
p53 expression and shRNA knockdown. For lentivirus 
knockdown experiments, the p53shRNA and pLKO 
vectors were purchased commercially (Vector Biolabs, 
Philadelphia, PA, #1854) and used as described by the 
manufacturer as previously described [15]. Briefly, 
293T cells (ATCC, Manassas, VA) were cotransfected 
with shRNA constructs along with the pHR′8.2ΔR and 
pCMV-VSV-G helper constructs. After 24 hours, the 
media was changed and the virus-containing media was 
harvested after an additional 24 hours of incubation. 
The MB cells were seeded at 30% confluency and viral 
infections were performed for 72 hours prior to treatment 
with VMY or DMSO.  Efficiency of the knockdown was 
monitored by p53 immunoblotting and quantification by 
ImageJ as previously described [15, 52, 53].  
 
Chemical inhibition of p53. For chemical inhibition of 
p53, 30uM Pifithrin-α (Sigma-Aldrich, St Louis, MO  
#P4359) was added one hour prior to treatment with 
VMY, doxorubicin or DMSO. 
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DNA fragmentation. D556 cells were infected with 
pLKO or p53shRNA virus’s for 72 hrs prior to 
treatment with VMY or DMSO. Doxorubicin was used 
as a positive control. The genomic DNA was isolated 
after 18 hr treatment with VMY or doxorubicin using 
the DNeasy blood and tissue kit (Qiagen, MD #69506). 
500ng of DNA was run on 1% agarose gel containing 
ethidium bromide with the electrophoresis carried out at 
100V for one hour.  
 
RNAseq and pathway analyses. Total RNA was 
extracted from D556 cells treated with Pif and VMY as 
described above using an RNeasy Plus Mini Kit 
(Qiagen, MD, #74134) and submitted to Otogenetics 
Corporation (Norcross, GA USA) for RNA-Seq assays. 
Sequencing was performed on the Illumina HiSeq 2500 
(20 million reads, Rapid run, Illumina, CA USA) with 
chemistry v1.0 and using the 2×106bp paired-end read 
mode and original chemistry from Illumina according to 
the manufacturer's instructions. The initial data analysis 
was started directly on the HiSeq 2500 System during 
the run. The HiSeq Control Software 2.0.5 in 
combination with RTA 1.17.20.0 (real time analysis) 
performed the initial image analysis and base calling. 
Quality control (QC) was performed using FastQC 
software. All the samples passed the "Basic Statistics", 
"Per Base Sequence Quality", "Per Sequence Quality 
Scores", "Per Base N Content", and "Sequence Length 
Distribution". No specific filtering was done for the 
samples. The final FASTQ files comprising the 
sequence information which was used for all subsequent 
bioinformatics analyses. Sequences were de-
multiplexed according to the 6bp index code with 1 
mismatch allowed. After QC, Tophat2 was used for the 
alignment, and BAM files were obtained. Partek 
Genomics Suite (6.6 version 6.12.0713 software (Partek 
Inc.) was utilized to calculate RPKM as normalization, 
and fold changes were calculated based on the RPKM 
results. The pathways analysis was performed through 
the use of QIAGEN’s Ingenuity® Pathway Analysis 




Cell cycle analyses were performed in the Lombardi 
Comprehensive Cancer Center’s Flow Cytometry 
Shared Resource, microscopy was performed in the 
Lombardi Comprehensive Cancer Center’s Microscopy 
and Imaging Shared Resource, the DNA fingerprint 
analyses were done through the Lombardi 
Comprehensive Cancer Center’s Tissue Culture Shared 
Resource and the RNAseq was performed through the 
Lombardi Comprehensive Cancer Center’s Genomics 
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Supplemental  Figure S1.  Immunoblotting  for  p53  following  exposure  of D556  cells  to  PVB  and VMY  for  the  times
indicated. b‐actin was used as a loading control. MWM (kDa); molecular weigh marker in kilodaltons. 
 
Supplemental Figure S2. Infection of MB cells with pLKO or p53shRNA. Three days
after infection, DAOY cells were either left untreated or exposed to DMSO or VMY for
18 hrs. Cell viability was determined by trypan blue dye exclusion. The data are shown
as average + standard deviation of N= 2 separate experiments. *; p < 0.05.  
